Table 3.
Phase I and Phase II Clinical Trials Evaluating the Effects of ICI and Angiogenic Inhibitor
| Cancer Types | Combination Regimen | Study Phase | Treatment | Clinical Trial ID(ref) | Clinical Outcomes |
|---|---|---|---|---|---|
| Resectable HCC | Camrelizumab + Apatinib | II | Neoadjuvant therapy | NCT0429720291 | MPR: 17.6%; pCR: 5.9% |
| Advanced non-squamous NSCLC (TMB high) | Atezolizumab + Bevacizumab | II | First-line | NCT0383606692 | 12-month PFS rate: 51.3% 12-month OS rate: 72.0% |
| EGFR+/ALK+ advanced NSCLC | Camrelizumab + Apatinib | Ib/II | ≥Second line | NCT0308304193 | ORR: 18.6% PFS: 2.8 m (95% CI 1.9–5.5) |
| Advanced NSCLC (PD-L1 positive) |
Pembrolizumab + Ramucirumab | Ia/b | ≥Second line | JVDF NCT0244332494 |
ORR: 42.3% PFS: 9.3 (95% CI 4.0-NR) |
| MSS mCRC | Regorafenib + Nivolumab |
Ib | ≥Second line | REGONIVO NCT0340687195 |
ORR: 33.3% 1-year PFS rate:41.8% 1-year OS rate: 68.0% |
| Non-MSI-H mCRC | Regorafenib + Avelumab | II | ≥Second line | REGOMUNE NCT0347595396 |
PFS: 3.6 m (95% CI 1.8–5.4) OS: 10.8 m (95% CI: 5.9–NA) |
| MSS/MSI-L/pMMR, relapsed or metastatic CRC | Regorafenib + Toripalimab | Ib/II | Second line | REGOTORI NCT0394691797 |
ORR: 15.2% PFS: 2.1 m (95% CI 2.0–4.3) OS: 15.5 m (95% CI 10.3-NA) |
| Advanced MSS CRC | Fruquintinib + Sintilimab | Ib/II | Second line | NCT0390370598 | ORR: 22.7% (5mg-intermittent group) PFS: 6.8 (95% CI:5.6-NA) |
| Non–MSI-H/Pmmr advanced CRC |
Lenvatinib + Pembrolizumab | II | ≥Second line | LEAP-005 NCT0379732699 |
ORR: 22% |